hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-25 and is reviewed periodically as new material appears.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Finally, as cold seeps become inactive, tubeworms also start to disappear, clearing the way for corals to settle on the now-exposed carbonate substrate. The corals do not rely on hydrocarbons seeping out of the seafloor. Studies on Lophelia pertusa suggest they derive their nutrition primarily from the ocean surface. Chemosynthesis plays only a very small role, if any, in their settlement and growth. While deepwater corals do not seem to be chemosynthesis-based organisms, the chemosynthetic organisms that come before them enable the corals' existence. This hypothesis about establishment of deep water coral reefs is called hydraulic theory.
== Simulation == In addition to experimental investigation of graphene and graphene-based devices, numerical modeling and simulation of graphene has also been an important research topic. The Kubo formula provides an analytic expression for the graphene's conductivity and shows that it is a function of several physical parameters including wavelength, temperature, and chemical potential. Moreover, a surface conductivity model, which describes graphene as an infinitesimally thin (two-sided) sheet with a local and isotropic conductivity, has been proposed. This model permits the derivation of analytical expressions for the electromagnetic field in the presence of a graphene sheet in terms of a dyadic Green function (represented using Sommerfeld integrals) and exciting electric current. Even though these analytical models and methods can provide results for several canonical problems for benchmarking purposes, many practical problems involving graphene, such as the design of arbitrarily shaped electromagnetic devices, are analytically intractable. With the recent advances in the field of computational electromagnetics (CEM), various accurate and efficient numerical methods have become available for analysis of electromagnetic field/wave interactions on graphene sheets and/or graphene-based devices. A comprehensive summary of computational tools developed for analyzing graphene-based devices/systems is proposed.
=== Diagnostic use === CRP is used mainly as an inflammation marker. Apart from liver failure, there are few known factors that interfere with CRP production. Interferon alpha inhibits CRP production from liver cells which may explain the relatively low levels of CRP found during viral infections compared to bacterial infections Measuring and charting CRP values can prove useful in determining disease progress or the effectiveness of treatments. ELISA and radial immunodiffusion methods are available for research use, while immunoturbidimetry is used clinically for CRP and nephelometry is typically used for hsCRP. Cutoffs for cardiovascular risk assessment have included:
Volatolomics is a development of metabolomics that studies volatile organic compounds (VOCs) emitted by a biological systems. Plant metabolomics is designed to study the overall changes in metabolites of plant samples and then conduct deep data mining and chemometric analysis. Specialized metabolites are considered components of plant defense systems biosynthesized in response to biotic and abiotic stresses. Metabolomics approaches have recently been used to assess the natural variance in metabolite content between individual plants, an approach with great potential for the improvement of the compositional quality of crops.
Sources: en.wikipedia.org
The United States Armed Forces' Meal, Ready-to-Eat (MRE) is packaged similarly to the Canadian ration. Each sealed plastic bag contains one entire precooked meal, with a number of supplements and accessories. The original 12 menus have been expanded to 24 and now contain a variety of ethnic and special request items as well. Kosher/Halal and Vegetarian menus are also provided. Each meal bag contains an 8-ounce (230 g) main course (packaged in a four-layer plastic and foil laminate retort pouch), 8 hardtack crackers, some form of spread (cheese, peanut butter, or jelly), a fruit-based beverage powder, some form of dessert (cake, candy, cookies, or fruit), and an accessory packet containing coffee or tea, creamer, sugar, salt, matches, a plastic spoon, and toilet paper. A chemical heater is packed with every meal. The First Strike Ration (FSR) is a compact, eat-on-the-move ration to be used for no more than three days during initial periods of highly intense, highly mobile combat assaults. A single FSR (24 hours food) is about 50% of the size and weight of three MREs. Each FSR provides 2,900 kcal (12,000 kJ) (15% protein, 53% carbohydrates, 34% fat), versus the 3,800 kcal (16,000 kJ) in three MREs, and has a two-year shelf life when stored at 80 °F (27 °C).
It is commonly used in lieu of boric acid and can be used to help control and possibly eliminate bed bugs, house dust mite, cockroach, ant, and flea infestations. Diatomaceous earth is widely applied for insect control in grain storage. It is used to control cannibalistic behaviors in confused flour beetles, which infest flour storages. To be effective as an insecticide, diatomaceous earth must have a mean particle size below about 12 μm (i.e., food grade—see below); and it must be uncalcinated (i.e., it must not be heat-treated prior to application). Although considered to be relatively low-risk, pesticides containing diatomaceous earth are not exempt from regulation in the United States under the Federal Insecticide, Fungicide, and Rodenticide Act and must be registered with the Environmental Protection Agency.
Stimulates the uptake of glucose – Insulin decreases blood glucose concentration by inducing intake of glucose by the cells. This is possible because Insulin causes the insertion of the GLUT4 transporter in the cell membranes of muscle and fat tissues which allows glucose to enter the cell. Increased fat synthesis – insulin forces fat cells to take in blood glucose, which is converted into triglycerides; decrease of insulin causes the reverse. Increased esterification of fatty acids – forces adipose tissue to make neutral fats (i.e., triglycerides) from fatty acids; decrease of insulin causes the reverse. Decreased lipolysis in – forces reduction in conversion of fat cell lipid stores into blood fatty acids and glycerol; decrease of insulin causes the reverse. Induced glycogen synthesis – When glucose levels are high, insulin induces the formation of glycogen by the activation of the hexokinase enzyme, which adds a phosphate group in glucose, thus resulting in a molecule that cannot exit the cell. At the same time, insulin inhibits the enzyme glucose-6-phosphatase, which removes the phosphate group. These two enzymes are key for the formation of glycogen. Also, insulin activates the enzymes phosphofructokinase and glycogen synthase which are responsible for glycogen synthesis.
Sources: en.wikipedia.org
=== Discontinued === Acamprosate controlled-release (SNC-102) – various actions [46] ALTO-202 – NMDA receptor antagonist [47] Balovaptan (RG-7314; RO-5028442; RO-5285119) – vasopressin V1 receptor antagonist [48] Brexpiprazole (Lu-AF41156; OPC-34712; Rexulti) – atypical antipsychotic (non-selective monoamine receptor modulator) [49] Carvedilol (Coreg) – α1-, β1-, and β2-adrenergic receptor antagonist and dual alpha/beta blocker [50] Crinecerfont (Crenessity; NBI-74788; SSR-125543) – corticotropin releasing factor receptor 1 (CRF1R) antagonist [51] ENX-105 – dopamine D2 and D3 receptor agonist, dopamine D4 receptor agonist, and serotonin 5-HT1A and 5-HT2A receptor agonist [52] Fluoxetine (Prozac, Sarafem) – selective serotonin reuptake inhibitor [53] Ganaxolone (GNX; CCD-1042; Ztalmy) – GABAA receptor positive allosteric modulator and neurosteroid [54] JZP-150 (PF-04457845; PF-4457845; PF-’845) – fatty acid amide hydrolase (FAAH) inhibitor [55] Nabiximols (tetrahydrocannabinol/cannabidiol; THC/CBD; GW-1000; JZP-378; Nabidiolex®/Tetranabinex®; Sativex) – cannabinoid receptor modulator, other actions [56] Naloxone/tianeptine (TNX-601) – combination of tianeptine (weak and atypical μ-opioid receptor agonist) and naloxone (orally inactive opioid receptor antagonist) Nepicastat (APL-1401; SYN-117) – dopamine β-hydroxylase (DBH) inhibitor [57] NYX-783 – NMDA receptor modulator [58] Orvepitant (GW-823296, GW823296X) – neurokinin NK1 receptor antagonist [59] Pomaglumetad methionil (DB103; LY-2140023; LY-2812223; LY-404039 prodrug) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist (pomaglumetad prodrug) [60] PRAX-114 – GABA modulator [61] PRX-3140 (PRX-03140; NTC-942) – serotonin 5-HT4 receptor agonist [62] Verucerfont (GSK-561679; NBI-77860) – corticotropin releasing factor receptor 1 (CRF1R) antagonist [63]
=== Pharmacodynamics === A-69024 is a selective dopamine D1 receptor antagonist. It shows high affinity for this receptor (Ki = 5.3–12.6 nM) and high selectivity for it over the dopamine D2 receptor (Ki = 1,290–1,320 nM; 102- to 249-fold lower affinity). Conversely, the drug shows very low affinity for the serotonin 5-HT2A and 5-HT2C receptors (Ki = >10,000 nM). On the other hand, it shows some affinity for the α2-adrenergic receptor (Ki = 95.5 nM) but not for the α1-adrenergic receptor (Ki = >1,000 nM). A-69024 blocks amphetamine- and cocaine-induced hyperlocomotion and apomorphine-induced stereotypy in rodents. It does not affect prolactin levels in rodents, unlike dopamine D2 receptor modulators. Along with SCH-23390, it produces aversive effects in rodents, whereas dopamine D2 receptor antagonists like spiperone and levosulpiride do not do so. The drug increases cocaine self-administration in rodents. Along with other dopamine D1 receptor antagonists, A-69024 has been found to block the head-twitch response induced by the serotonergic psychedelic DOI. Similarly, dopamine D2 receptor antagonists were likewise found to block the DOI-induced head-twitch response.
Though originally planned to be presented at a ceremony at the Queen Elizabeth Hall in London, the event was instead presented as a live stream on 2 April 2020 due to concern over the COVID-19 pandemic.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.